Recombinant lactic acid bacteria as mucosal biotherapeutic agents |
| |
| Authors: | Daniel Catherine Roussel Yvonne Kleerebezem Michiel Pot Bruno |
| |
| Institution: | 1Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Université Lille Nord de France, CNRS, UMR 8204, Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France;2Unité de Recherche sur l’Animal et les Fonctionnalités des Produits Animaux, Equipe protéolyse–Biofonctionnalité des protéines et peptides, Faculté des Sciences et Techniques, UHP, Nancy Université, B.P. 239 54506 Vandoeuvre-les-Nancy Cedex, France;3Health Department, NIZO Food Research, P.O. Box 20, 6710 BA Ede, The Netherlands;4Laboratory of Microbiology, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, The Netherlands |
| |
| Abstract: | The safety status of lactic acid bacteria (LAB) and their capacity to survive the passage through the gastrointestinal tract (GI tract) have rendered them excellent candidates for the production of therapeutic proteins and their delivery in situ to the GI tract. During the past two decades, major health benefits of mucosally administered recombinant LAB have been successfully demonstrated, predominantly using animal models. However, the field has recently moved into the era of human clinical trials. In this review, we provide a timely update on the recent important advances made in this field, and outline the potential of recombinant LAB as therapeutic tools for their safe and efficient use in human health. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
